These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1386916)

  • 1. Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones.
    Davies SW; Beardsall K
    Neurosci Lett; 1992 Jun; 140(2):161-4. PubMed ID: 1386916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sparing of cholinergic neurons following quinolinic acid lesions of the rat striatum.
    Davies SW; Roberts PJ
    Neuroscience; 1988 Aug; 26(2):387-93. PubMed ID: 2971892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of neurotrophin-4/5 and transforming growth factor-alpha on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid.
    Alexi T; Venero JL; Hefti F
    Neuroscience; 1997 May; 78(1):73-86. PubMed ID: 9135090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions.
    Beal MF; Kowall NW; Swartz KJ; Ferrante RJ; Martin JB
    Synapse; 1989; 3(1):38-47. PubMed ID: 2563916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolinic acid does not spare striatal neuropeptide Y-immunoreactive neurons.
    Boegman RJ; Smith Y; Parent A
    Brain Res; 1987 Jul; 415(1):178-82. PubMed ID: 2957024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids.
    Schumacher JM; Short MP; Hyman BT; Breakefield XO; Isacson O
    Neuroscience; 1991; 45(3):561-70. PubMed ID: 1837849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
    Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
    Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease.
    Pérez-Navarro E; Canudas AM; Akerund P; Alberch J; Arenas E
    J Neurochem; 2000 Nov; 75(5):2190-9. PubMed ID: 11183872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats.
    Figueredo-Cardenas G; Anderson KD; Chen Q; Veenman CL; Reiner A
    Exp Neurol; 1994 Sep; 129(1):37-56. PubMed ID: 7925841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic infusion of quinolinic acid in rat striatum: effects on discrete neuronal populations.
    Forloni GL; Angeretti N; Rizzi M; Vezzani A
    J Neurol Sci; 1992 Apr; 108(2):129-36. PubMed ID: 1387677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idebenone attenuates neuronal degeneration induced by intrastriatal injection of excitotoxins.
    Miyamoto M; Coyle JT
    Exp Neurol; 1990 Apr; 108(1):38-45. PubMed ID: 2138566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid.
    Foster AC; Vezzani A; French ED; Schwarcz R
    Neurosci Lett; 1984 Aug; 48(3):273-8. PubMed ID: 6237279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATP as a marker of excitotoxin-induced nerve cell death in vivo.
    Vezzani A; Sangalli L; Wu HQ; Schwarcz R
    J Neural Transm; 1987; 70(3-4):349-56. PubMed ID: 2960779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates.
    Koliatsos VE; Clatterbuck RE; Nauta HJ; Knüsel B; Burton LE; Hefti FF; Mobley WC; Price DL
    Ann Neurol; 1991 Dec; 30(6):831-40. PubMed ID: 1789695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of nerve growth factor's effects on development of septum, striatum, and nucleus basalis cholinergic neurons in vitro.
    Hartikka J; Hefti F
    J Neurosci Res; 1988; 21(2-4):352-64. PubMed ID: 3216428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nigrostriatal pathway modulates striatum vulnerability to quinolinic acid.
    Buisson A; Pateau V; Plotkine M; Boulu RG
    Neurosci Lett; 1991 Oct; 131(2):257-9. PubMed ID: 1837072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal implants protect the host striatum against quinolinic acid toxicity.
    Pearlman SH; Levivier M; Collier TJ; Sladek JR; Gash DM
    Exp Brain Res; 1991; 84(2):303-10. PubMed ID: 1829685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease.
    Kordower JH; Charles V; Bayer R; Bartus RT; Putney S; Walus LR; Friden PM
    Proc Natl Acad Sci U S A; 1994 Sep; 91(19):9077-80. PubMed ID: 8090772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term consequences of intracranial injections of the excitotoxin, quinolinic acid, as evidenced by GFA immunohistochemistry of astrocytes.
    Björklund H; Olson L; Dahl D; Schwarcz R
    Brain Res; 1986 Apr; 371(2):267-77. PubMed ID: 2938667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types.
    Figueredo-Cardenas G; Harris CL; Anderson KD; Reiner A
    Exp Neurol; 1998 Feb; 149(2):356-72. PubMed ID: 9500958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.